CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Abacavir

阿巴卡韦 杂质对照品Abacavir Impurities

EPUSP45 个杂质条目45 impurity entries

本页汇总 阿巴卡韦 的 45 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 45 impurity reference standards of Abacavir with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 阿巴卡韦(Abacavir)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStress Degradation Behavior of Abacavir Sulfate and Development of a Suitable Stability-Indicating UHPLC Method for the Determination of Abacavir, its Related Substances, and Degradation Products
    Scientia pharmaceutica · 2012 · Vukkum P et al.  ·  PMID 23264939  ·  DOI
  2. 杂质研究Impurity studiesDevelopment and validation of a reverse-phase liquid chromatographic method for assay and related substances of abacavir sulfate
    Journal of separation science · 2007 · Seshachalam U et al.  ·  PMID 17313138  ·  DOI
  3. 杂质研究Impurity studiesSeparation and characterization of forced degradation products of abacavir sulphate by LC-MS/MS
    Journal of pharmaceutical and biomedical analysis · 2011 · Rao RN et al.  ·  PMID 20869185  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisSynthesis of (R)- and (S)-4-Hydroxy-2-cyclopenten-1-ones: Total Synthesis of Entecavir, Abacavir, and Carbovir
    The Journal of organic chemistry · 2025 · Li N et al.  ·  PMID 40910633  ·  DOI
  • 合成方法SynthesisEnantioselective and Regiodivergent Addition of Purines to Terminal Allenes: Synthesis of Abacavir
    Angewandte Chemie (International ed. in English) · 2017 · Thieme N, Breit B  ·  PMID 28079946  ·  DOI

阿巴卡韦 —— 原料药与杂质对照品Abacavir — drug substance & impurities

共 46 个条目(含原料药本体)46 items incl. the drug substance
Abacavir structure
EP原料药 APIAPI
阿巴卡韦Abacavir
Abacavir
CAS No.136470-78-5
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir EP Impurity A structure
EPA
阿巴卡韦杂质1 (硫酸阿巴卡韦EP杂质A)Abacavir EP Impurity A
Abacavir EP Impurity A
CAS No.136470-79-6
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir EP Impurity B structure
EPB
阿巴卡韦EP杂质BAbacavir EP Impurity B
Abacavir EP Impurity B
CAS No.1443421-69-9
Chemical FormulaC18H21ClN10O
Purity>95%现货In stock
10mg25mg50mg100mg
Abacavir EP Impurity C structure
EPC
阿巴卡韦杂质3 (硫酸阿巴卡韦EP杂质C)Abacavir EP Impurity C
Abacavir EP Impurity C
CAS No.124752-25-6
Chemical FormulaC11H14N6O
Purity>95%询价On request
10mg25mg50mg100mg
ent-Abacavir EP Impurity C structure
EPC
阿巴卡韦EP杂质Cent-Abacavir EP Impurity C
ent-Abacavir EP Impurity C
CAS No.—
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir EP Impurity D HCl structure
EPD
阿巴卡韦EP杂质D 盐酸盐(RR)Abacavir EP Impurity D HCl
Abacavir EP Impurity D HCl
CAS No.1443421-67-7
Chemical FormulaC14H18N6O
Purity>95%现货In stock
10mg25mg50mg100mg
ent-Abacavir EP Impurity D structure
EPD
阿巴卡韦杂质29ent-Abacavir EP Impurity D
ent-Abacavir EP Impurity D
CAS No.2079853-44-2
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir EP Impurity E structure
EPE
阿巴卡韦杂质5 (硫酸阿巴卡韦EP杂质E)Abacavir EP Impurity E
Abacavir EP Impurity E
CAS No.208762-35-0
Chemical FormulaC14H20N6O
Purity>95%询价On request
10mg25mg50mg100mg
N-Nitroso Abacavir EP Impurity E structure
EPE
N-Nitroso Abacavir EP Impurity E
CAS No.—
Chemical FormulaC14H17N7O2
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir EP Impurity F structure
EPF
阿巴卡韦EP杂质FAbacavir EP Impurity F
Abacavir EP Impurity F
CAS No.1443421-68-8
Chemical FormulaC18H26N6O
Purity>95%现货In stock
10mg25mg50mg100mg
Abacavir USP Related Compound C structure
USPC
阿巴卡韦杂质8(阿巴卡韦USP相关化合物C)Abacavir USP Related Compound C
Abacavir USP Related Compound C
CAS No.172015-79-1
Chemical FormulaC11H13Cl2N5O
Purity>95%询价On request
10mg25mg50mg100mg
Cyclopropyl Diaminopurine Abacavir structure
—
阿巴卡韦杂质10Cyclopropyl Diaminopurine Abacavir
Cyclopropyl Diaminopurine Abacavir
CAS No.120503-69-7
Chemical FormulaC8H10N6
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir 5’-Phosphate structure
—
阿巴卡韦杂质13Abacavir 5’-Phosphate
Abacavir 5’-Phosphate
CAS No.136470-77-4
Chemical FormulaC14H19N6O4P
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir N-Oxide structure
—
阿巴卡韦杂质19Abacavir N-Oxide
Abacavir N-Oxide
CAS No.1443421-70-2
Chemical FormulaC14H18N6O2
Purity>95%询价On request
10mg25mg50mg100mg
N-Nitroso Abacavir structure
—
N-Nitroso Abacavir
CAS No.—
Chemical FormulaC14H17N7O2
Purity>95%询价On request
10mg25mg50mg100mg
ent-Abacavir Carboxylate Trifluoroacetate structure
—
ent-Abacavir Carboxylate Trifluoroacetate
CAS No.—
Chemical FormulaC14H16N6O2.C2HF3O2
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir-5'-glucuronide structure
—
Abacavir-5'-glucuronide
CAS No.—
Chemical FormulaC20H26N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Carboxylate Trifluoroacetate structure
—
Abacavir Carboxylate Trifluoroacetate
CAS No.—
Chemical FormulaC14H16N6O2.C2HF3O2
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity (3-Hydroxy Abacavir) structure
—
阿巴卡韦杂质Abacavir Impurity (3-Hydroxy Abacavir)
Abacavir Impurity (3-Hydroxy Abacavir)
CAS No.—
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 2 structure
2
阿巴卡韦杂质2Abacavir Impurity 2
Abacavir Impurity 2
CAS No.—
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 4 Dihydrochloride structure
4
阿巴卡韦杂质4 双盐酸盐Abacavir Impurity 4 Dihydrochloride
Abacavir Impurity 4 Dihydrochloride
CAS No.267668-71-3
Chemical FormulaC14H18N6O·2HCl
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 4 structure
4
阿巴卡韦杂质4Abacavir Impurity 4
Abacavir Impurity 4
CAS No.783292-37-5
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 5 structure
5
阿巴卡韦杂质5Abacavir Impurity 5
Abacavir Impurity 5
CAS No.—
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 6 structure
6
阿巴卡韦杂质6Abacavir Impurity 6
Abacavir Impurity 6
CAS No.—
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 7 structure
7
阿巴卡韦杂质7Abacavir Impurity 7
Abacavir Impurity 7
CAS No.171887-01-7
Chemical FormulaC10H14Cl2N6
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 8 structure
8
阿巴卡韦杂质8Abacavir Impurity 8
Abacavir Impurity 8
CAS No.171887-02-8
Chemical FormulaC7H9Cl2N5
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 9 structure
9
阿巴卡韦杂质7Abacavir Impurity 9
Abacavir Impurity 9
CAS No.141271-12-7
Chemical FormulaC10H14ClN5O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 10 HCl structure
10
阿巴卡韦杂质32Abacavir Impurity 10 HCl
Abacavir Impurity 10 HCl
CAS No.2211067-09-1
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 11 structure
11
阿巴卡韦杂质11Abacavir Impurity 11
Abacavir Impurity 11
CAS No.1904-98-9
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 12 structure
12
阿巴卡韦杂质12Abacavir Impurity 12
Abacavir Impurity 12
CAS No.—
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 13 structure
13
阿巴卡韦杂质13Abacavir Impurity 13
Abacavir Impurity 13
CAS No.2663884-03-3
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 14 structure
14
阿巴卡韦杂质14Abacavir Impurity 14
Abacavir Impurity 14
CAS No.384380-52-3
Chemical FormulaC14H16N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 20 structure
20
阿巴卡韦杂质20Abacavir Impurity 20
Abacavir Impurity 20
CAS No.79200-56-9
Chemical FormulaC6H7NO
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 21 structure
21
阿巴卡韦杂质21Abacavir Impurity 21
Abacavir Impurity 21
CAS No.153064-93-8
Chemical FormulaC14H20N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 22 structure
22
阿巴卡韦杂质22Abacavir Impurity 22
Abacavir Impurity 22
CAS No.384329-76-4
Chemical FormulaC20H26N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 23 structure
23
阿巴卡韦杂质23Abacavir Impurity 23
Abacavir Impurity 23
CAS No.49805-30-3
Chemical FormulaC6H7NO
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 24 structure
24
阿巴卡韦杂质24Abacavir Impurity 24
Abacavir Impurity 24
CAS No.121864-74-2
Chemical FormulaC11H16N5O11P3
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 25 structure
25
阿巴卡韦杂质25Abacavir Impurity 25
Abacavir Impurity 25
CAS No.72784-43-1
Chemical FormulaC5H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 26 structure
26
阿巴卡韦杂质26Abacavir Impurity 26
Abacavir Impurity 26
CAS No.2022943-79-7
Chemical FormulaC11H14ClN5O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 27 structure
27
阿巴卡韦杂质27Abacavir Impurity 27
Abacavir Impurity 27
CAS No.906626-51-5
Chemical FormulaC11H14N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 30 structure
30
阿巴卡韦杂质30Abacavir Impurity 30
Abacavir Impurity 30
CAS No.128131-83-9
Chemical FormulaC14H18N6O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 31 structure
31
阿巴卡韦杂质31Abacavir Impurity 31
Abacavir Impurity 31
CAS No.178327-20-3
Chemical FormulaC11H12ClN5O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 37 structure
37
阿巴卡韦杂质37Abacavir Impurity 37
Abacavir Impurity 37
CAS No.2125943-52-2
Chemical FormulaC10H14ClN5O
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 39 structure
39
阿巴卡韦杂质39Abacavir Impurity 39
Abacavir Impurity 39
CAS No.171887-04-0
Chemical FormulaC11H14ClN5O2
Purity>95%询价On request
10mg25mg50mg100mg
Abacavir Impurity 4-d4 structure
4-D4
阿巴卡韦杂质4-d4Abacavir Impurity 4-d4
Abacavir Impurity 4-d4
CAS No.1346747-48-5
Chemical FormulaC14H14D4N6O
Purity>95%询价On request
Abacavir Impurity 30-d4 structure
30-D4
阿巴卡韦杂质30-d4Abacavir Impurity 30-d4
Abacavir Impurity 30-d4
CAS No.1217731-56-0
Chemical FormulaC14H14D4N6O
Purity>95%询价On request
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

阿巴卡韦 —— 研究文献与合成路线Abacavir — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 阿巴卡韦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Abacavir. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stress Degradation Behavior of Abacavir Sulfate and Development of a Suitable Stability-Indicating UHPLC Method for the Determination of Abacavir, its Related Substances, and Degradation Products
    Vukkum P, Deshpande GR, Babu JM, et al. · Scientia pharmaceutica · 2012 · 被引 6cited 6
  2. Stability behaviour of antiretroviral drugs and their combinations. 5: Characterization of novel degradation products of abacavir sulfate by mass and nuclear magnetic resonance spectrometry
    Kurmi M, Sahu A, Singh S · Journal of pharmaceutical and biomedical analysis · 2017 · 被引 13cited 13
  3. Separation and characterization of forced degradation products of abacavir sulphate by LC-MS/MS
    Rao RN, Vali RM, Ramachandra B, et al. · Journal of pharmaceutical and biomedical analysis · 2011 · 被引 14cited 14
  4. Forced degradation study of abacavir using the electrochemistry-mass spectrometry setup
    Vymyslický F, Fischer J, Heřt J, et al. · Journal of pharmaceutical and biomedical analysis · 2026
  5. Development and validation of a reverse-phase liquid chromatographic method for assay and related substances of abacavir sulfate
    Seshachalam U, Haribabu B, Chandrasekhar KB · Journal of separation science · 2007 · 被引 5cited 5
  6. Analytical Method Development and Validation for the Simultaneous Estimation of Abacavir and Lamivudine by Reversed-phase High-performance Liquid Chromatography in Bulk and Tablet Dosage Forms
    Raees Ahmad SA, Patil L, Mohammed Usman MR, et al. · Pharmacognosy research · 2018 · 被引 1cited 1

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION OF ABACAVIR
    CAMPON PARDO JULIO, BERENGUER MAIMO RAMON, MEDRANO RUPEREZ JORGE, ELIAS RIUS LAIA · 公开号 MX2009006231MX2009006231 · 2009
  2. PROCESS FOR THE PREPARATION OF ABACAVIR
    MEDRANO RUPEREZ JORGE, CAMPON PARDO JULIO, ELIAS RIUS LAIA, BERENGUER MAIMO RAMON · 公开号 KR20090054459KR20090054459 · 2009
  3. PROCESS FOR THE PREPARATION OF ABACAVIR
    CAMPON PARDO JULIO, BERENGUER MAIMO RAMON, MEDRANO RUPEREZ JORGE, ELIAS RIUS LAIA · 公开号 MX2009002446MX2009002446 · 2009
  4. Process for the preparation of abacavir
    MEDRANO RUPEREZ JORGE, CAMPON PARDO JULIO, ELIAS RIUS LAIA, BERENGUER MAIMO RAMON · 公开号 US2010041883US2010041883 · 2010
  5. PROCESS FOR THE PREPARATION OF ABACAVIR
    MEDRANO RUPEREZ JORGE, CAMPON PARDO JULIO, ELIAS RIUS LAIA, BERENGUER MAIMO RAMON · 公开号 EP2125814EP2125814 · 2009

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

阿巴卡韦 杂质谱研究要点Abacavir — impurity profiling notes

下面这些是拿到 阿巴卡韦 的 46 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 46 impurity entries for Abacavir, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances